Compare SXC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | IRWD |
|---|---|---|
| Founded | 1960 | 1998 |
| Country | United States | United States |
| Employees | 848 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 621.1M | 663.6M |
| IPO Year | 2011 | 2009 |
| Metric | SXC | IRWD |
|---|---|---|
| Price | $7.64 | $3.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $9.00 | $7.67 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $1,600,300,000.00 | $298,276,000.00 |
| Revenue This Year | N/A | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $15.23 |
| Revenue Growth | ★ 10.30 | 8.88 |
| 52 Week Low | $5.52 | $0.55 |
| 52 Week High | $8.92 | $5.78 |
| Indicator | SXC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 68.97 | 39.56 |
| Support Level | $7.21 | $3.07 |
| Resistance Level | $8.34 | $3.92 |
| Average True Range (ATR) | 0.31 | 0.33 |
| MACD | 0.08 | -0.11 |
| Stochastic Oscillator | 78.61 | 7.45 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.